Lot No: 1
II.2.1) Title
Low-tech Homecare Medicines Services
II.2.2) Additional CPV code(s)
85149000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Members of the East of England NHS Collaborative Procurement Hub's Pharmacy Procurement Model and members of NHS Commercial Solutions.
II.2.4) Description of the procurement
This lot captures low-tech homecare medicines services.
This includes, but is not limited to, provision of homecare services for the following areas:
— HIV,
— Hepatitis,
— Oral Chemotherapy,
— Immunosuppression,
— Erythropoetin Stimulating Agents (ESAs),
— Oral and Inhaled Antibiotic Products,
— Self-injectable Methotrexate,
— Self-Injectable Biologic Products for Rheumatology, Dermatology, Gastroenterology and Neurology Indications,
— Other Products requiring low-tech service.
Low-tech homecare medicines services will be as defined in the ITT documents which closely aligns to the definitions detailed in the Royal Pharmaceutical Society Professional Standards for Homecare.
In brief this can be categorised as dispense and deliver of products for self-administration including, where appropriate, supply of sharps bin and associated waste collection services.
This Framework Agreement will include, and be for the benefit of publically funded (both wholly and partially funded) entities in the United Kingdom, including Northern Ireland, Scotland, Wales and England. This will include, but is not limited to: Acute, Ambulance, Mental Health, Clinical Commissioning Groups, Health and Care Trusts, Area Teams, Local Authorities and Special Health Authorities, HSC in Northern Ireland, NHS Scotland and NHS Wales, including any successor or emerging organisations, which will include but is not limited to the emerging landscape of combined health and social care commissioners and providers. Please follow the links below to identify specific organisations:
— NHS trusts: http://www.nhs.uk/ServiceDirectories/Pages/AcuteTrustListing.aspx
— Clinical Commissioning Groups: http://www.nhs.uk/ServiceDirectories/Pages/CCGListing.aspx
— Area Teams: http://www.nhs.uk/ServiceDirectories/Pages/AreaTeamListing.aspx
— Local Authorities: https://www.lgbce.org.uk/records-and-resources/local-authorities-in-england
— Special health authorities: http://www.nhs.uk/ServiceDirectories/Pages/SpecialHealthAuthorityListing.aspx
— HSC in Northern Ireland: http://online.hscni.net/other-hsc-organisations
— NHS Scotland: http://www.scot.nhs.uk/organisations/
— NHS Wales: http://www.wales.nhs.uk/ourservices/directory
II.2.5) Award criteria
Quality criterion: General
/ Weighting: 18 %
Quality criterion: Prescribing and Dispensing
/ Weighting: 5 %
Quality criterion: Delivery
/ Weighting: 15 %
Quality criterion: Cold Chain / Controlled Drug / Hazardous Medicines
/ Weighting: 5 %
Quality criterion: Governance
/ Weighting: 9 %
Quality criterion: Finance
/ Weighting: 5 %
Quality criterion: Equipment and Ancillaries
/ Weighting: 2 %
Quality criterion: Prescribing and Dispensing (additional lot 1)
/ Weighting: 1 %
Cost criterion: Price for Evaluation
/ Weighting: 40 %
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
Mid-tech Homecare Medicines Services
II.2.2) Additional CPV code(s)
85149000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Members of the East of England NHS Collaborative Procurement Hub Pharmacy Procurement Model and NHS Commercial Solutions. Members are primarily situated in the East of England and South East Coast.
II.2.4) Description of the procurement
This lot captures mid-tech homecare medicines services.
This includes, but is not limited to, provision of homecare services for the following areas:
— Hepatitis,
— Oral Chemotherapy,
— Self-injectable Methotrexate,
— Erythropoetin Stimulating Agents (ESAs),
— Self-Injectable Biologic Products for Rheumatology, Dermatology, Gastroenterology and Neurology Indications,
— Other Products requiring mid-tech service.
Mid-tech homecare medicines services will be as defined in the ITT documents which closely aligns to the definitions detailed in the Royal Pharmaceutical Society Professional Standards for Homecare.
In brief this can be categorised as dispense and deliver of products for self-administration including, where appropriate, supply of sharps bin and associated waste collection services as well as provision of initial patient training / competency assessment or supply of equipment e.g. refrigerator where required.
This Framework Agreement will include, and be for the benefit of publicly funded (both wholly and partially funded) entities in the United Kingdom, including Northern Ireland, Scotland, Wales and England. This will include, but is not limited to: Acute, Ambulance, Mental Health, Clinical Commissioning Groups, Health and Care Trusts, Area Teams, Local Authorities and Special Health Authorities, HSC in Northern Ireland, NHS Scotland and NHS Wales, including any successor or emerging organisations, which will include but is not limited to the emerging landscape of combined health and social care commissioners and providers. Please follow the links below to identify specific organisations:
— NHS trusts: http://www.nhs.uk/ServiceDirectories/Pages/AcuteTrustListing.aspx
— Clinical Commissioning Groups: http://www.nhs.uk/ServiceDirectories/Pages/CCGListing.aspx
— Area Teams: http://www.nhs.uk/ServiceDirectories/Pages/AreaTeamListing.aspx
— Local Authorities: https://www.lgbce.org.uk/records-and-resources/local-authorities-in-england
— Special health authorities: http://www.nhs.uk/ServiceDirectories/Pages/SpecialHealthAuthorityListing.aspx
— HSC in Northern Ireland: http://online.hscni.net/other-hsc-organisations
— NHS Scotland: http://www.scot.nhs.uk/organisations/
— NHS Wales: http://www.wales.nhs.uk/ourservices/directory
II.2.5) Award criteria
Quality criterion: General
/ Weighting: 13 %
Quality criterion: Prescribing and Dispensing
/ Weighting: 5 %
Quality criterion: Delivery
/ Weighting: 10 %
Quality criterion: Cold chain / controlled drug / hazardous medicines
/ Weighting: 5 %
Quality criterion: Governance
/ Weighting: 10 %
Quality criterion: Finance
/ Weighting: 5 %
Quality criterion: General (additional lot 2)
/ Weighting: 1 %
Quality criterion: Cold chain / controlled drug / hazardous medicines (additional Lot 2)
/ Weighting: 1 %
Quality criterion: Equipment and Ancillaries
/ Weighting: 2.5 %
Quality criterion: Clinical Services and Home Visits
/ Weighting: 7.5 %
Cost criterion: Dispense and Delivery Services Price for Evaluation
/ Weighting: 20 %
Cost criterion: Clinical Services Price for Evaluation
/ Weighting: 10 %
Cost criterion: Equipment Price for Evaluation
/ Weighting: 10 %
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
High-tech Homecare Medicines Services for Antibiotic Products
II.2.2) Additional CPV code(s)
85149000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Members of the East of England NHS Collaborative Procurement Hub Pharmacy Procurement Model and NHS Commercial Solutions. Members are primarily situated in the East of England and South East Coast.
II.2.4) Description of the procurement
This lot capture high-tech homecare medicines services for antibiotic products.
This lot includes application to, but is not limited to, the following indications and services:
— Compounded injectable antibiotic products for cystic fibrosis requiring high-tech homecare service activities,
— Compounded injectable antibiotic products for other therapeutic indications,
— Outpatient Parenteral Antibiotic Therapy (OPAT) / Early discharge,
— Admission avoidance,
— Supplementary oral or uncompounded antibiotic products.
The scope of this Lot is to reflect the current and future requirements of the Participating Authorities and includes the incorporation of new developments in the field which offer benefits to both patient experience and product / service costs. Such developments include, but are not limited to new antibiotic products brought to market, extended stability data and continuous infusions.
This Framework Agreement will include, and be for the benefit of publically funded (both wholly and partially funded) entities in the United Kingdom, including Northern Ireland, Scotland, Wales and England. This will include, but is not limited to: Acute, Ambulance, Mental Health, Clinical Commissioning Groups, Health and Care Trusts, Area Teams, Local Authorities and Special Health Authorities, HSC in Northern Ireland, NHS Scotland and NHS Wales, including any successor or emerging organisations, which will include but is not limited to the emerging landscape of combined health and social care commissioners and providers. Please follow the links below to identify specific organisations:
— NHS trusts: http://www.nhs.uk/ServiceDirectories/Pages/AcuteTrustListing.aspx
— Clinical Commissioning Groups: http://www.nhs.uk/ServiceDirectories/Pages/CCGListing.aspx
— Area Teams: http://www.nhs.uk/ServiceDirectories/Pages/AreaTeamListing.aspx
— Local Authorities: https://www.lgbce.org.uk/records-and-resources/local-authorities-in-england
— Special health authorities: http://www.nhs.uk/ServiceDirectories/Pages/SpecialHealthAuthorityListing.aspx
— HSC in Northern Ireland: http://online.hscni.net/other-hsc-organisations
— NHS Scotland: http://www.scot.nhs.uk/organisations/
— NHS Wales: http://www.wales.nhs.uk/ourservices/directory
II.2.5) Award criteria
Quality criterion: General
/ Weighting: 10 %
Quality criterion: Prescribing and Dispensing
/ Weighting: 3 %
Quality criterion: Delivery
/ Weighting: 10 %
Quality criterion: Cold Chain / Controlled Drug / Hazardous Medicines
/ Weighting: 4 %
Quality criterion: Governance
/ Weighting: 10 %
Quality criterion: Finance
/ Weighting: 3 %
Quality criterion: Lot Specific Questions (too many categories to list in OJEU form)
/ Weighting: 20 %
Cost criterion: Evaluation Scenario 1
/ Weighting: 4 %
Cost criterion: Evaluation Scenario 2
/ Weighting: 4 %
Cost criterion: Evaluation Scenario 3
/ Weighting: 4 %
Cost criterion: Evaluation Scenario 4
/ Weighting: 4 %
Cost criterion: Evaluation Scenario 5
/ Weighting: 4 %
Cost criterion: Evaluation Scenario 6
/ Weighting: 4 %
Cost criterion: Evaluation Scenario 7
/ Weighting: 4 %
Cost criterion: Evaluation Scenario 8
/ Weighting: 4 %
Cost criterion: Evaluation Scenario 9
/ Weighting: 4 %
Cost criterion: Evaluation Scenario 10
/ Weighting: 4 %
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 4
II.2.1) Title
High-Tech Homecare Medicines Services
II.2.2) Additional CPV code(s)
85149000
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Members of the East of England NHS Collaborative Procurement Hub Pharmacy Procurement Model and NHS Commercial Solutions. Members are primarily situated in the East of England and South East Coast.
II.2.4) Description of the procurement
This lot, Lot 4 (High-tech homecare medicines services), of the East of England NHS Collaborative Procurement Hub framework agreement for the provision of homecare medicines services captures high-tech homecare services, as defined in the core specification. Services procured under this lot will typically be, but are not limited to:
— Services where nurse administration is required to be undertaken by the Contractor
and/or
— Services which include provision of aseptic compounded of products.
This lot is for further competition only and provides a framework for Purchasing Authorities to establish bespoke high-tech homecare services.
This Framework Agreement will include, and be for the benefit of publicly funded (both wholly and partially funded) entities in the United Kingdom, including Northern Ireland, Scotland, Wales and England. This will include, but is not limited to: Acute, Ambulance, Mental Health, Clinical Commissioning Groups, Health and Care Trusts, Area Teams, Local Authorities and Special Health Authorities, HSC in Northern Ireland, NHS Scotland and NHS Wales, including any successor or emerging organisations, which will include but is not limited to the emerging landscape of combined health and social care commissioners and providers. Please follow the links below to identify specific organisations:
— NHS trusts: http://www.nhs.uk/ServiceDirectories/Pages/AcuteTrustListing.aspx
— Clinical Commissioning Groups: http://www.nhs.uk/ServiceDirectories/Pages/CCGListing.aspx
— Area Teams: http://www.nhs.uk/ServiceDirectories/Pages/AreaTeamListing.aspx
— Local Authorities: https://www.lgbce.org.uk/records-and-resources/local-authorities-in-england
— Special health authorities: http://www.nhs.uk/ServiceDirectories/Pages/SpecialHealthAuthorityListing.aspx
— HSC in Northern Ireland: http://online.hscni.net/other-hsc-organisations
— NHS Scotland: http://www.scot.nhs.uk/organisations/
— NHS Wales: http://www.wales.nhs.uk/ourservices/directory
II.2.5) Award criteria
Quality criterion: General
/ Weighting: 10 %
Quality criterion: Prescribing and Dispensing
/ Weighting: 3 %
Quality criterion: Delivery
/ Weighting: 10 %
Quality criterion: Cold Chain / Controlled Drug / Hazardous Medicines
/ Weighting: 4 %
Quality criterion: Governance
/ Weighting: 10 %
Quality criterion: Finance
/ Weighting: 3 %
Quality criterion: Lot specific (categories exceed max OJEU can capture)
/ Weighting: 20 %
Cost criterion: Core Service
/ Weighting: 14 %
Cost criterion: Clinical visits
/ Weighting: 13 %
Cost criterion: Equipment
/ Weighting: 13 %
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
The contract has been awarded to a group of economic operators:
Yes
The contract has been awarded to a group of economic operators:
Yes
The contract has been awarded to a group of economic operators:
Yes
The contract has been awarded to a group of economic operators:
Yes